Gimoti denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gimoti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Step Therapy to Gimoti

Step therapy — sometimes called "fail first" — requires that a patient try one or more lower-cost alternatives before the plan will cover a preferred or specialty drug. For Gimoti (metoclopramide nasal spray), BCBS typically requires documented use of oral metoclopramide (and possibly other agents) as a prerequisite. The denial occurs because either (a) the records submitted did not document a prior trial of the required step drug(s), or (b) no prior-authorization documenting the step was submitted before the prescription was filled.

## Why This Denial Is Appealable

Step-therapy denials are appealable on two distinct grounds. First, if the patient already tried and failed (or cannot tolerate) the required prior step, that clinical history — with dates and documentation — satisfies the step and the appeal should succeed. Second, if a clinical exception applies — such as a contraindication to the step drug, or a clinical reason why the oral route is not viable — most plans have a step-therapy exception process that runs parallel to or faster than a formal appeal. Many states now have step-therapy reform laws that codify patient rights to exceptions; the federal mental-health parity rules also limit certain step-therapy applications.

## Your Federal Appeal Rights

• Step-therapy exception (fastest path): If an exception criterion applies, submit the exception request with clinical documentation to BCBS's pharmacy or medical management team immediately.
• Internal appeal (ERISA §503 / ACA §2719): File a formal written internal appeal within the deadline on the denial notice. The plan must provide a clinical peer review and a written decision.
• External review (ACA §2719): After internal exhaustion, request independent external review. External reviewers apply clinical standards — not just plan rules — and can overturn step-therapy denials where the clinical record supports the prescribed drug. Decisions arrive within 45 days standard or 72 hours expedited.
• State step-therapy law: Check whether your state has enacted step-therapy protections that establish specific exception timelines or criteria favorable to patients.

## Documentation to Gather

• Prior-step drug trial records: Prescription history for oral metoclopramide and any other step drugs the plan requires — include dates, duration, and documented outcomes or adverse effects.
• Reason oral route is inadequate (if applicable): Chart notes and prescriber explanation of why absorption via oral route is unreliable or why the patient cannot tolerate the oral formulation.
• Clinical severity documentation: Gastric-emptying study, physician notes on symptom burden, and any hospitalizations or urgent-care visits related to gastroparesis.
• Prescriber medical-necessity letter: A structured letter referencing the FDA-approved prescribing information for Gimoti and addressing each step-therapy criterion the plan applies, with specific chart citations.

## Criteria-Mapping Structure

Obtain the step-therapy criteria from BCBS's published coverage policy or the denial notice, then complete this table:

| Step Requirement | Documentation Provided | |---|---| | Required prior therapy 1 (e.g., oral metoclopramide) | [Prescription date, duration, outcome/intolerance noted in chart] | | Required prior therapy 2 (if applicable) | [Same format] | | Exception criterion (if bypass requested) | [Clinical reason, prescriber letter, FDA label reference] |

A well-organized step-therapy appeal that systematically checks every box in the plan's own criteria — rather than arguing clinically in the abstract — has the highest probability of reversal at the internal level, before external review is even needed.